Toron Inc (TRON) 0.0004 $TRON
David Reid Joins Motiga as Senior Vice President, Publishing
Business Wire - Thu Sep 18, 8:10AM CDT
Motiga, the independent online game studio behind Gigantic, today announced David Reid has joined the company as Senior Vice President, Publishing. The move signifies the company's commitment to build world-class publishing infrastructure for Gigantic. Motiga has been stealthily working on Gigantic -- a free-to-play PC action game -- for two years, and after a successful showing at PAX Prime, has officially brought the game into public alpha testing. Reid joins Motiga's executive team alongside CEO and Co-Founder Chris Chung, CTO and Co-Founder Rick Lambright, and VP Product Development James Phinney.
FiltersFast.com Celebrates the Fourth of July with Special Shipping Offer
PRWeb - Mon Jul 07, 4:26AM CDT
In celebration of Independence Day Filtersfast.com, the leading online retailer of air and water filters, is offering customers another free shipping deal. This is to thank loyal customers by giving them one more reason to celebrate. All purchases on FiltersFast.com, of $50.00 or more, will be eligible to receive free shipping during this limited, promotional period of July 4 - July 7, 2014.
Epithelial Ovarian Cancer - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5l7bgr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Boehringer Ingelheim GmbH - Amgen Inc. - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - ImmunoGen, Inc. - Bayer AG - Pharmacyclics, Inc. - Prima BioMed Ltd. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - Glycotope GmbH - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - CerRx, Inc. - Immunotope, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Clovis Oncology, Inc. - Recepta Biopharma S.A. - California Stem Cell, Inc. - EGEN, Inc. - AbbVie Inc. - Sotio a.s. For more information visit http://www.researchandmarkets.com/research/5l7bgr/epithelial
Crawford Advisors Enhances Team with the Addition of Peggy Whelan and Ashley Law
PRWeb - Tue Mar 18, 6:19PM CDT
Crawford Advisors, LLC, one of its region's largest full-service benefits and consulting brokerage firms, serving businesses across America, today announced that Peggy Whelan and Ashley Law have joined its organization. Whelan has assumed the responsibilities of an individual disability practice leader, and Law has joined the firm as a sales executive.
2014 Air Filters and Filtration Equipment Global Strategic Business Report - Air Filter Companies Pursue Consolidation and Geographic Expansion
M2 - Thu Mar 13, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c64x8/air_filters_and) has announced the addition of the "Air Filters and Filtration Equipment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Air Filters and Filtration Equipment in US$ Million by the following Product Segments: Automotive Air Filters, Cartridge Air Filters, Electrostatic Air Filters, Fabric Air Pollution Filters, HVAC Air Filters, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET TRENDS, ISSUES AND DRIVERS 3. GLOBAL FILTRATION AND SEPARATION MARKET: A MACRO PERSPECTIVE 4. AIR FILTRATION - AN OVERVIEW 5. MAJOR END-USE SECTORS: AN OVERVIEW 6. PRODUCT INNOVATIONS/LAUNCHES - K&N Engineering Unveils K&N High-Flow Air Filter - Clarcor Air Filtration Products Rolls out Nano-Pak Bag Airfilter - American Air Filter Unveils MEGApleat M8 Pleated Filter - CORTECO Launches micronAir? Cabin Filters - AAF International Introduces VariSorb XL15 Particulate and Gas-Phase Filter - Atlas Copco Compressors Introduces New Range of Air Filters - Losma India Launches Darwin Series Centrifugal Air Filters - Asian Filtration Technology Introduces Air Filter Range - Valeo Unveils Cabin Air Filter - Ahlstrom Unveils Novel Filtration Media, Flow2Save - HEPAirX? Obtains 510(K) Clearance from the FDA - Airocide Introduces New Air Purifier - Hurricane Air Filters Unveils Stainless Mesh Air Filter - 3M Launches Filtrete Odor Reduction Filter - MANN HUMMEL Introduces Flame-Retardant Air Filters - Dust Free Unveils Micropure Total Home Active Air Purifier - Air Filters Launches Novel 4-Season Filter - Clean Air America Launches Two Novel ScandMist Air Filtration Systems - Air Filters Launches Novel Range of Air Filter Housings - Ahlstrom Introduces Range of Heavy-Duty Media XAir for Airfilters of Automobile Engines - DiscountFurnaceFilter.com Introduces Full Range of 3M Filtrete Filters - AAF International Introduces New VariCel ? XL HT Air Filters - Schenck Process Expands its Product Range to Include Novel MCF Filter System - Dwyer Instruments Launches AFR2 Instrument Series Air Filter - Federal-Mogul Launches Champion? Brand in Automotive Filtration - Federal-Mogul Rolls Out Air Filters 7. RECENT INDUSTRY ACTIVITY - Engineered Data Files Patent for the World's First Air Filter Made from Nanoporous Iron Oxide Particles - AAF International and LPD Technologies Collaborate - Filtration Group Acquires AG Industries - AAF International Takes Over CEI - CLARCOR Inks Agreement to Take over GE's Air Filtration Business - MANN HUMMEL FAWAY Filter Establishes New Filter Production Plant in China - AAF Establishes New Manufacturing Facility in Shah Alam - Freudenberg Expands Operations in Europe - Camfil Enhances Research Facilities - Nederman Holding to Acquire Environmental Filtration Technologies - Henry Schein Secures Product Distribution Rights from AtmosAir Solutions - Noveko Signs Supply Agreement with Air Transat - Vokes Air Merges with Filtac - Parker Hannifin Takes over Filtration Business of John Fowler - Insight Equity Holdings Acquires Flanders - Pentair Filtration Solutions Takes over Carl Prandtl MicroFiltration - Corac Group To Acquire Wellman Defence and Wellman Hunt Graham - Epurair Bags Contract from Societe de Transport de Montreal Buildings - AAF International to Launch Air Filtration Technology - BMC Ventures into Indian Market with Performance Air Filters - OHL Engineering Acquires MANN HUMMEL ProTec - Freudenberg Filtration Technologies India Takes Over Pyramid Filters India - Pall Corporation Sells Blood Collection, Filtration and Processing Products Groups to Haemonetics - SPX Acquires Disk Centrifuges Company Seital - SPX Takes Over CLYDEUNION Pumps - Filtration Group Takes Over Universal Air Filter 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 209 companies including many key and niche players such as: - 3M Company - A.L.Filter - Aerospace America - Ahlstrom - Air Filter Service - Aristech Japan - American Air Filter (AAF) - Bruce Air Filter - Camfil - Clarcor Air Filtration Products - Cummins - Donaldson - Dust Free - Filtration Group - Filtration Systems Products - Flanders - Freudenberg & Co. - GVS - Hollingsworth & Vose - Lydall - Mann Hummel - Midwesco Filter Resources - Nordic Air Filtration - Purafil - Sogefi - Spectrum Filtration - Superior Fibers - Trion - UCI-FRAM - FRAM Filtration For more information visit http://www.researchandmarkets.com/research/3c...ilters_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Trion Worlds Announces Glyph Digital Games Platform
Business Wire - Tue Mar 11, 11:00AM CDT
Trion Worlds, global developer and publisher of premium online games, has officially announced Glyph, a new lightweight digital hub for PC games and their digital goods. Glyph will introduce the more than 10 million players that have signed on with Trion Worlds to a curated collection of quality games, including Trion titles as well as games from hand-picked partners.
Concise Analysis of the International Bispecific Antibody Therapeutics Market
M2 - Tue Mar 04, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/c63zqb/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering. Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease. With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III. The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4. CURRENT MARKET AND FORECAST 5. TECHNOLOGY PLATFORMS 6. PROFILES OF LEADING COMPANIES 7. SWOT ANALYSIS 8. CONCLUSIONS 9. LIST OF COMPANIES AND ORGANISATIONS 10. TABLES Companies Mentioned: - Abbvie - Ablynx - BMS - Boehringer Ingelheim - Celgene - Chiome Bioscience - Chromacon - Chugai - Covagen - Dow Pharma - Dutalys - EMD Serono - Eli Lilly - Emergent - Epigen Biotech - Fabion Pharmaceuticals - GSK - Imclone Systems - Mitsubishi Tanabe - Molecular Partners AG - Novartis - Novimmune - Numab - OcellO - Oncomed - OtSuka Pharma - Paktis Antibody Services GmbH - Pfizer - Synimmune - Tanabe Research Labs - Trion - UCB-Celltech - X-Body Biosciences - Xencor - Zymeworks - Zymogenetics - Zyngenia For more information visit http://www.researchandmarkets.com/research/c63zqb/bispecific
Research and Markets: Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
Business Wire - Mon Mar 03, 11:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/cz4wj5/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering.
Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
M2 - Mon Mar 03, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/bm4r24/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering. Since the Global Electrostatic Precipitator market is highly competitive, manufacturers are providing new and innovative solutions and exploring new application areas for the existing range of products to stay ahead of the competition. Moreover, growing environmental and health concerns have led vendors to focus on the development of products that have higher efficiency and lower power consumption. There is increased expenditure in the market on the R&D of new products and services. More research is being undertaken on upgrading and optimizing the performance of electrostatic precipitators used in different industries. The growth of the Global Electrostatic Precipitator market is driven by several factors, the most important of which is the increase in demand from the APAC region. The growth of the market in this region is positively influenced by government policies to reduce the emissions associated with coal-fired power generation. Further, the report states that one of the key challenges in this market is the growing popularity of fabric filters over electrostatic precipitators. The key vendors dominating this market space are: - Alstom SA - Blacke-Durr GmbH - The Babcock & Wilcox Co. - Trion Inc. Other vendors mentioned in the report are: - Clean Tunnel Air International AS - Siemens AG - Total Air Pollution Control Pty Ltd. For more information visit http://www.researchandmarkets.com/research/bm4r24/global
Crawford Advisors Expands Account Management Team with Raymond Daniels and Leanna Krug
PRWeb - Wed Feb 19, 3:08AM CST
Crawford Advisors, LLC, one of its region's largest full-service benefits and consulting brokerage firms, serving businesses across America, today announced that Raymond Daniels has assumed the position of account manager and Leanna Krug has been appointed assistant accounts manager.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Trion IAQ Expands its IAQ Line with a New Disposable Filter Program
PRWeb - Tue Feb 04, 7:08AM CST
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, announced today its expansion of their residential air filtration line of products. The Trion Residential Disposable Filter Program includes pleated, polyester, and fiberglass disposable filters. Trion strives to continue offering its loyal and potential customers a complete line of indoor air quality solutions.
Filtration.com Now Carries Trion Air Bear(R) Furnace Filters
PRWeb - Wed Sep 18, 9:31AM CDT
Filtration.com, a premier indoor air quality online store is proud to announce the newest addition to their product line, Trion Air Bear(R) filters. Trion is an aftermarket media air filter that fits in models from Generalaire(R), Skuttle(R), Ultravation(R) and their own Trion air purification system - Trion Air Bear Cub Air Cleaner.
Peritoneal Cancer - Pipeline Review, H2 2013 Report will Assist you in Planning Mergers and Acquisitions Effectively by Identifying Players of the Most Promising Pipeline
M2 - Mon Aug 12, 10:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgbb5m/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peritoneal Cancer. - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: AstraZeneca PLC GlaxoSmithKline plc Oxford BioMedica plc Millennium Pharmaceuticals, Inc. Novartis AG Bayer AG Incyte Corporation EntreMed, Inc. Oncolytics Biotech Inc. Synta Pharmaceuticals Corp. Oasmia Pharmaceutical AB Spectrum Pharmaceuticals, Inc. Acceleron Pharma, Inc. TRION Pharma GmbH TetraLogic Pharmaceuticals CritiTech, Inc. ImmunoVaccine Technologies Inc. VentiRx Pharmaceuticals, Inc. Genelux Corporation For more information visit http://www.researchandmarkets.com/research/zg...eal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fallopian Tube Cancer - Pipeline Review, H2 2013: Plan Mergers and Acquisitions Effectively By Identifying Players
M2 - Fri Aug 09, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fs44g/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Fallopian Tube Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. Scope - A snapshot of the global therapeutic scenario for Fallopian Tube Cancer. - A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - Acceleron Pharma, Inc. - Amgen Inc. - AstraZeneca PLC - Boehringer Ingelheim GmbH - Cell Therapeutics, Inc. - Daiichi Sankyo Company, Ltd - Eli Lilly and Company - EntreMed, Inc. - GlaxoSmithKline plc - ImmunoVaccine Technologies Inc. - Incyte Corporation - Marshall Edwards, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - Oncolytics Biotech Inc. - Oxford BioMedica plc - RECEPTA Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRACON Pharmaceuticals, Inc. - TRION Pharma GmbH - TetraLogic Pharmaceuticals - VentiRx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/7f...lopian_tub About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epithelial Ovarian Cancer - Latest Pipeline Review Report
M2 - Wed Aug 07, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62k5jl/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. 'Epithelial Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer. Scope - A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer. - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Epithelial Ovarian Cancer Therapeutics Development - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Oxford BioMedica plc - Novartis AG - Astellas Pharma Inc. - Bayer AG - Prima BioMed Limited - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - RECEPTA Biopharma S.A. Drug Profiles - trebananib - sorafenib tosylate - elesclomol - paclitaxel - TroVax - MEK-162 - nintedanib - catumaxomab - CVac - VTX-2337 - levonorgestrel - plevitrexed - RebmAb-100 - cositecan - EGEN-001 - NY-ESO-1 Overlapping Peptides Vaccine - Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - HER-2/Neu Specific T Cells - MV-NIS Vaccine - pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Globo-H-GM2-sTn-TF-Tn-KLH Conjugate [QS-21] - DCVAC/OvCa For more information visit http://www.researchandmarkets.com/research/62k5jl/epithelial
Trion(R) Introduces a Motorized Air Damper for the Residential Market
PRWeb - Tue Aug 06, 8:07AM CDT
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, is proud to introduce the latest product offering in residential indoor air quality. The Trion Motorized Damper (TMD520) is designed to introduce fresh air into the building envelope through an intake damper that is controlled by the microprocessor-based ventilation control interface. The system controls the amount of outdoor ventilation, promoting healthier indoor air quality, required by the Ventilation and Air Quality Standard defined in ASHRAE 62.2. This standard defines the roles of, and minimum requirements for, mechanical and natural ventilation systems and the building envelope intended to provide acceptable indoor air quality (IAQ) in low-rise residential buildings.
David Reid Joins Motiga as Senior Vice President, Publishing
Business Wire - Thu Sep 18, 8:10AM CDT
Motiga, the independent online game studio behind Gigantic, today announced David Reid has joined the company as Senior Vice President, Publishing. The move signifies the company's commitment to build world-class publishing infrastructure for Gigantic. Motiga has been stealthily working on Gigantic -- a free-to-play PC action game -- for two years, and after a successful showing at PAX Prime, has officially brought the game into public alpha testing. Reid joins Motiga's executive team alongside CEO and Co-Founder Chris Chung, CTO and Co-Founder Rick Lambright, and VP Product Development James Phinney.
FiltersFast.com Celebrates the Fourth of July with Special Shipping Offer
PRWeb - Mon Jul 07, 4:26AM CDT
In celebration of Independence Day Filtersfast.com, the leading online retailer of air and water filters, is offering customers another free shipping deal. This is to thank loyal customers by giving them one more reason to celebrate. All purchases on FiltersFast.com, of $50.00 or more, will be eligible to receive free shipping during this limited, promotional period of July 4 - July 7, 2014.
Epithelial Ovarian Cancer - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5l7bgr/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Boehringer Ingelheim GmbH - Amgen Inc. - Oxford BioMedica plc - Millennium Pharmaceuticals, Inc. - ImmunoGen, Inc. - Bayer AG - Pharmacyclics, Inc. - Prima BioMed Ltd. - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - Glycotope GmbH - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - CerRx, Inc. - Immunotope, Inc. - Pharma Mar, S.A. - VentiRx Pharmaceuticals, Inc. - Clovis Oncology, Inc. - Recepta Biopharma S.A. - California Stem Cell, Inc. - EGEN, Inc. - AbbVie Inc. - Sotio a.s. For more information visit http://www.researchandmarkets.com/research/5l7bgr/epithelial
Crawford Advisors Enhances Team with the Addition of Peggy Whelan and Ashley Law
PRWeb - Tue Mar 18, 6:19PM CDT
Crawford Advisors, LLC, one of its region's largest full-service benefits and consulting brokerage firms, serving businesses across America, today announced that Peggy Whelan and Ashley Law have joined its organization. Whelan has assumed the responsibilities of an individual disability practice leader, and Law has joined the firm as a sales executive.
2014 Air Filters and Filtration Equipment Global Strategic Business Report - Air Filter Companies Pursue Consolidation and Geographic Expansion
M2 - Thu Mar 13, 4:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3c64x8/air_filters_and) has announced the addition of the "Air Filters and Filtration Equipment - Global Strategic Business Report" report to their offering. This report analyzes the worldwide markets for Air Filters and Filtration Equipment in US$ Million by the following Product Segments: Automotive Air Filters, Cartridge Air Filters, Electrostatic Air Filters, Fabric Air Pollution Filters, HVAC Air Filters, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2012 through 2020. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. Key Topics Covered I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS II. EXECUTIVE SUMMARY 1. INDUSTRY OVERVIEW 2. MARKET TRENDS, ISSUES AND DRIVERS 3. GLOBAL FILTRATION AND SEPARATION MARKET: A MACRO PERSPECTIVE 4. AIR FILTRATION - AN OVERVIEW 5. MAJOR END-USE SECTORS: AN OVERVIEW 6. PRODUCT INNOVATIONS/LAUNCHES - K&N Engineering Unveils K&N High-Flow Air Filter - Clarcor Air Filtration Products Rolls out Nano-Pak Bag Airfilter - American Air Filter Unveils MEGApleat M8 Pleated Filter - CORTECO Launches micronAir? Cabin Filters - AAF International Introduces VariSorb XL15 Particulate and Gas-Phase Filter - Atlas Copco Compressors Introduces New Range of Air Filters - Losma India Launches Darwin Series Centrifugal Air Filters - Asian Filtration Technology Introduces Air Filter Range - Valeo Unveils Cabin Air Filter - Ahlstrom Unveils Novel Filtration Media, Flow2Save - HEPAirX? Obtains 510(K) Clearance from the FDA - Airocide Introduces New Air Purifier - Hurricane Air Filters Unveils Stainless Mesh Air Filter - 3M Launches Filtrete Odor Reduction Filter - MANN HUMMEL Introduces Flame-Retardant Air Filters - Dust Free Unveils Micropure Total Home Active Air Purifier - Air Filters Launches Novel 4-Season Filter - Clean Air America Launches Two Novel ScandMist Air Filtration Systems - Air Filters Launches Novel Range of Air Filter Housings - Ahlstrom Introduces Range of Heavy-Duty Media XAir for Airfilters of Automobile Engines - DiscountFurnaceFilter.com Introduces Full Range of 3M Filtrete Filters - AAF International Introduces New VariCel ? XL HT Air Filters - Schenck Process Expands its Product Range to Include Novel MCF Filter System - Dwyer Instruments Launches AFR2 Instrument Series Air Filter - Federal-Mogul Launches Champion? Brand in Automotive Filtration - Federal-Mogul Rolls Out Air Filters 7. RECENT INDUSTRY ACTIVITY - Engineered Data Files Patent for the World's First Air Filter Made from Nanoporous Iron Oxide Particles - AAF International and LPD Technologies Collaborate - Filtration Group Acquires AG Industries - AAF International Takes Over CEI - CLARCOR Inks Agreement to Take over GE's Air Filtration Business - MANN HUMMEL FAWAY Filter Establishes New Filter Production Plant in China - AAF Establishes New Manufacturing Facility in Shah Alam - Freudenberg Expands Operations in Europe - Camfil Enhances Research Facilities - Nederman Holding to Acquire Environmental Filtration Technologies - Henry Schein Secures Product Distribution Rights from AtmosAir Solutions - Noveko Signs Supply Agreement with Air Transat - Vokes Air Merges with Filtac - Parker Hannifin Takes over Filtration Business of John Fowler - Insight Equity Holdings Acquires Flanders - Pentair Filtration Solutions Takes over Carl Prandtl MicroFiltration - Corac Group To Acquire Wellman Defence and Wellman Hunt Graham - Epurair Bags Contract from Societe de Transport de Montreal Buildings - AAF International to Launch Air Filtration Technology - BMC Ventures into Indian Market with Performance Air Filters - OHL Engineering Acquires MANN HUMMEL ProTec - Freudenberg Filtration Technologies India Takes Over Pyramid Filters India - Pall Corporation Sells Blood Collection, Filtration and Processing Products Groups to Haemonetics - SPX Acquires Disk Centrifuges Company Seital - SPX Takes Over CLYDEUNION Pumps - Filtration Group Takes Over Universal Air Filter 8. FOCUS ON SELECT PLAYERS 9. GLOBAL MARKET PERSPECTIVE III. MARKET 1. THE UNITED STATES 2. CANADA 3. JAPAN 4. EUROPE 5. ASIA-PACIFIC 6. LATIN AMERICA 7. REST OF WORLD IV. COMPETITIVE LANDSCAPE Companies Mentioned The report profiles 209 companies including many key and niche players such as: - 3M Company - A.L.Filter - Aerospace America - Ahlstrom - Air Filter Service - Aristech Japan - American Air Filter (AAF) - Bruce Air Filter - Camfil - Clarcor Air Filtration Products - Cummins - Donaldson - Dust Free - Filtration Group - Filtration Systems Products - Flanders - Freudenberg & Co. - GVS - Hollingsworth & Vose - Lydall - Mann Hummel - Midwesco Filter Resources - Nordic Air Filtration - Purafil - Sogefi - Spectrum Filtration - Superior Fibers - Trion - UCI-FRAM - FRAM Filtration For more information visit http://www.researchandmarkets.com/research/3c...ilters_and About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Trion Worlds Announces Glyph Digital Games Platform
Business Wire - Tue Mar 11, 11:00AM CDT
Trion Worlds, global developer and publisher of premium online games, has officially announced Glyph, a new lightweight digital hub for PC games and their digital goods. Glyph will introduce the more than 10 million players that have signed on with Trion Worlds to a curated collection of quality games, including Trion titles as well as games from hand-picked partners.
Concise Analysis of the International Bispecific Antibody Therapeutics Market
M2 - Tue Mar 04, 6:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/c63zqb/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering. Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986. A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease. With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III. The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously. Key Topics Covered: 1. EXECUTIVE SUMMARY 2. INTRODUCTION 3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES 4. CURRENT MARKET AND FORECAST 5. TECHNOLOGY PLATFORMS 6. PROFILES OF LEADING COMPANIES 7. SWOT ANALYSIS 8. CONCLUSIONS 9. LIST OF COMPANIES AND ORGANISATIONS 10. TABLES Companies Mentioned: - Abbvie - Ablynx - BMS - Boehringer Ingelheim - Celgene - Chiome Bioscience - Chromacon - Chugai - Covagen - Dow Pharma - Dutalys - EMD Serono - Eli Lilly - Emergent - Epigen Biotech - Fabion Pharmaceuticals - GSK - Imclone Systems - Mitsubishi Tanabe - Molecular Partners AG - Novartis - Novimmune - Numab - OcellO - Oncomed - OtSuka Pharma - Paktis Antibody Services GmbH - Pfizer - Synimmune - Tanabe Research Labs - Trion - UCB-Celltech - X-Body Biosciences - Xencor - Zymeworks - Zymogenetics - Zyngenia For more information visit http://www.researchandmarkets.com/research/c63zqb/bispecific
Research and Markets: Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
Business Wire - Mon Mar 03, 11:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/cz4wj5/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering.
Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating
M2 - Mon Mar 03, 10:36AM CST
Research and Markets (http://www.researchandmarkets.com/research/bm4r24/global) has announced the addition of the "Global Electrostatic Precipitator Market to 2018 with Alstom, Blacke-Durr, Babcock & Wilcox & Trion Dominating" report to their offering. Since the Global Electrostatic Precipitator market is highly competitive, manufacturers are providing new and innovative solutions and exploring new application areas for the existing range of products to stay ahead of the competition. Moreover, growing environmental and health concerns have led vendors to focus on the development of products that have higher efficiency and lower power consumption. There is increased expenditure in the market on the R&D of new products and services. More research is being undertaken on upgrading and optimizing the performance of electrostatic precipitators used in different industries. The growth of the Global Electrostatic Precipitator market is driven by several factors, the most important of which is the increase in demand from the APAC region. The growth of the market in this region is positively influenced by government policies to reduce the emissions associated with coal-fired power generation. Further, the report states that one of the key challenges in this market is the growing popularity of fabric filters over electrostatic precipitators. The key vendors dominating this market space are: - Alstom SA - Blacke-Durr GmbH - The Babcock & Wilcox Co. - Trion Inc. Other vendors mentioned in the report are: - Clean Tunnel Air International AS - Siemens AG - Total Air Pollution Control Pty Ltd. For more information visit http://www.researchandmarkets.com/research/bm4r24/global
Crawford Advisors Expands Account Management Team with Raymond Daniels and Leanna Krug
PRWeb - Wed Feb 19, 3:08AM CST
Crawford Advisors, LLC, one of its region's largest full-service benefits and consulting brokerage firms, serving businesses across America, today announced that Raymond Daniels has assumed the position of account manager and Leanna Krug has been appointed assistant accounts manager.
Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors
M2 - Mon Feb 17, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/xx9pc7/competitor) has announced the addition of the Competitor Analysis: CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors report to their offering. The present Competitive Intelligence Report about CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of February 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2013 sales of over US$ 7.7 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Sales of rituximab for treatment of rheumatoid athritis makes out 17.1% of total Rituxan (US) / MabThera (EU) sales.Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are developing 2nd and 3rd generation CD20 antibodies as a measure to protect against emerging rituximab biosimilars. In fact, second generation anti-CD20 antibody Gazyva has already been approved and launched in ist first indication. The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in off-patent countries, but also in phase III studies in Western regulated markets. The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on: - Drug Codes, - Target / Mechanism of Action, - Class of Compound, - Company, - Product Category, - Indication, - R&D Stage and - additional comments with a hyperlink leading to the source of information. About Competitor Analysis Series: The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced. Key Topics Covered: 1. CD20 Antibodies - Rituximab Biosimilars and Biobetters/Biosuperiors Marketed CD20 Antibodies & Sales - Rituxan/MabThera Pipeline & Sales - Arzerra Pipeline & Sales - Gazyva Pipeline & Sales - Bexxar & Zevalin Pipeline & Sales Biosuperior CD20 Antibodies Biosimilar CD20 Antibodies - Rituxan/MabThera (rituximab) Biosimilars - Arzerra (ofatumumab) Biosimilars 2. Corporate CD20 Antibody Biosimilar & Biobetter Pipelines Companies Mentioned: - Actavis (Watson Pharmaceuticals) - Alopexx Oncology - Amgen - Aprogen - Competitor Analysis - Innovent Biologics - Intas Pharmaceuticals - Lentigen - LG Life Sciences - Libbs Farmaceutica - Mabxience - Mentrik Biotech - Merck - Molecular Templates - Natco Pharma - Nichi-Iko Pharmaceutical - Oncobiologics - PanGenerika - PanPharmaceuticals USA - Pfizer - PharmaPraxis - PlantForm - Probiomed - rEVO Biologics - Roche - Sandoz (Novartis) - Shanghai CP Guojian Pharmaceutical Co - Shanghai Henliu Biopharmaceuticals - Spectrum Pharmaceuticals - STADA Arzneimittel 68 - TG Therapeutics - Therapeutics Protein International (TPI) - TRION Pharma - Vaccinex - Valor Biotherapeutics - Viropro - Zhejiang Huahai Pharmaceutical Co For more information visit http://www.researchandmarkets.com/research/xx9pc7/competitor About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Trion IAQ Expands its IAQ Line with a New Disposable Filter Program
PRWeb - Tue Feb 04, 7:08AM CST
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, announced today its expansion of their residential air filtration line of products. The Trion Residential Disposable Filter Program includes pleated, polyester, and fiberglass disposable filters. Trion strives to continue offering its loyal and potential customers a complete line of indoor air quality solutions.
Filtration.com Now Carries Trion Air Bear(R) Furnace Filters
PRWeb - Wed Sep 18, 9:31AM CDT
Filtration.com, a premier indoor air quality online store is proud to announce the newest addition to their product line, Trion Air Bear(R) filters. Trion is an aftermarket media air filter that fits in models from Generalaire(R), Skuttle(R), Ultravation(R) and their own Trion air purification system - Trion Air Bear Cub Air Cleaner.
Peritoneal Cancer - Pipeline Review, H2 2013 Report will Assist you in Planning Mergers and Acquisitions Effectively by Identifying Players of the Most Promising Pipeline
M2 - Mon Aug 12, 10:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgbb5m/peritoneal_cancer) has announced the addition of the "Peritoneal Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Peritoneal Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Peritoneal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Peritoneal Cancer. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Peritoneal Cancer. - A review of the Peritoneal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Peritoneal Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: AstraZeneca PLC GlaxoSmithKline plc Oxford BioMedica plc Millennium Pharmaceuticals, Inc. Novartis AG Bayer AG Incyte Corporation EntreMed, Inc. Oncolytics Biotech Inc. Synta Pharmaceuticals Corp. Oasmia Pharmaceutical AB Spectrum Pharmaceuticals, Inc. Acceleron Pharma, Inc. TRION Pharma GmbH TetraLogic Pharmaceuticals CritiTech, Inc. ImmunoVaccine Technologies Inc. VentiRx Pharmaceuticals, Inc. Genelux Corporation For more information visit http://www.researchandmarkets.com/research/zg...eal_cancer About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Fallopian Tube Cancer - Pipeline Review, H2 2013: Plan Mergers and Acquisitions Effectively By Identifying Players
M2 - Fri Aug 09, 6:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7fs44g/fallopian_tube) has announced the addition of the "Fallopian Tube Cancer - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Fallopian Tube Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Fallopian Tube Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fallopian Tube Cancer. Scope - A snapshot of the global therapeutic scenario for Fallopian Tube Cancer. - A review of the Fallopian Tube Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Fallopian Tube Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 - Acceleron Pharma, Inc. - Amgen Inc. - AstraZeneca PLC - Boehringer Ingelheim GmbH - Cell Therapeutics, Inc. - Daiichi Sankyo Company, Ltd - Eli Lilly and Company - EntreMed, Inc. - GlaxoSmithKline plc - ImmunoVaccine Technologies Inc. - Incyte Corporation - Marshall Edwards, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Oasmia Pharmaceutical AB - Oncolytics Biotech Inc. - Oxford BioMedica plc - RECEPTA Biopharma S.A. - Spectrum Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - TRACON Pharmaceuticals, Inc. - TRION Pharma GmbH - TetraLogic Pharmaceuticals - VentiRx Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/7f...lopian_tub About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Epithelial Ovarian Cancer - Latest Pipeline Review Report
M2 - Wed Aug 07, 8:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/62k5jl/epithelial) has announced the addition of the "Epithelial Ovarian Cancer - Pipeline Review, H2 2013" report to their offering. 'Epithelial Ovarian Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epithelial Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer. Scope - A snapshot of the global therapeutic scenario for Epithelial Ovarian Cancer. - A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Epithelial Ovarian Cancer pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Involved in Epithelial Ovarian Cancer Therapeutics Development - Boehringer Ingelheim GmbH - Amgen Inc. - AstraZeneca PLC - Oxford BioMedica plc - Novartis AG - Astellas Pharma Inc. - Bayer AG - Prima BioMed Limited - Synta Pharmaceuticals Corp. - Oasmia Pharmaceutical AB - TRION Pharma GmbH - BioNumerik Pharmaceuticals, Inc. - VentiRx Pharmaceuticals, Inc. - RECEPTA Biopharma S.A. Drug Profiles - trebananib - sorafenib tosylate - elesclomol - paclitaxel - TroVax - MEK-162 - nintedanib - catumaxomab - CVac - VTX-2337 - levonorgestrel - plevitrexed - RebmAb-100 - cositecan - EGEN-001 - NY-ESO-1 Overlapping Peptides Vaccine - Carcinoembryonic Antigen-Expressing Measles Virus Vaccine - HER-2/Neu Specific T Cells - MV-NIS Vaccine - pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine - Globo-H-GM2-sTn-TF-Tn-KLH Conjugate [QS-21] - DCVAC/OvCa For more information visit http://www.researchandmarkets.com/research/62k5jl/epithelial
Trion(R) Introduces a Motorized Air Damper for the Residential Market
PRWeb - Tue Aug 06, 8:07AM CDT
Trion(R), an innovative, international company dedicated to providing quality products for the commercial, industrial, and residential markets since 1947, is proud to introduce the latest product offering in residential indoor air quality. The Trion Motorized Damper (TMD520) is designed to introduce fresh air into the building envelope through an intake damper that is controlled by the microprocessor-based ventilation control interface. The system controls the amount of outdoor ventilation, promoting healthier indoor air quality, required by the Ventilation and Air Quality Standard defined in ASHRAE 62.2. This standard defines the roles of, and minimum requirements for, mechanical and natural ventilation systems and the building envelope intended to provide acceptable indoor air quality (IAQ) in low-rise residential buildings.
